



DEPARTMENT OF HEALTH & HUMAN SERVICES

SEP 29 2009

Food and Drug Administration
Rockville MD 20857

Re: Degarelix
Docket No. FDA-2009-E-2006

The Honorable David J. Kappos
Under Secretary of Commerce for Intellectual Property
Director of the United States Patent and Trademark Office
Mail Stop Hatch-Waxman PTE
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Director Kappos:

This is in regard to the application for patent term extension for U.S. Patent No. 5,925,730 filed by Ferring BV, under 35 U.S.C. § 156. The human drug product claimed by the patent is Degarelix (degarelix acetate), which was assigned new drug application (NDA) No. 22-201.

A review of the Food and Drug Administration's official records indicates that this product was subject to a regulatory review period before its commercial marketing or use, as required under 35 U.S.C. § 156(a)(4). Our records also indicate that it represents the first permitted commercial marketing or use of the product, as defined under 35 U.S.C. § 156(f)(1).

The NDA was approved on December 24, 2008, which makes the submission of the patent term extension application on February 12, 2009, timely within the meaning of 35 U.S.C. § 156(d)(1).

Should you conclude that the subject patent is eligible for patent term extension, please advise us accordingly. As required by 35 U.S.C. § 156(d)(2)(A) we will then determine the applicable regulatory review period, publish the determination in the *Federal Register*, and notify you of our determination.

Please let me know if we can be of further assistance.

Sincerely yours,

Jane A. Axelrad
Associate Director for Policy
Center for Drug Evaluation and Research

cc: Charles E. Van Horn
Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
Customer No. 22852
901 New York Avenue, N.W.
Washington, DC 20001-4413